Risperidone liquisolid compacts–Formulation and evaluation

The present research is aimed to enhance the dissolution rate of risperidone, low soluble drug. The absorption rate of risperidone is often controlled by the dissolution rate in the GIT due to its poor solubility. The liquisolid compacts (LSC), a promising technique, was employed to overcome low solubility issue. Different formulations were developed using carriers (Neusilin and Fugicalin), coating (aerosil 200) and vehicle (propylene glycol). The empirical method as introduced by Spireas and Bolton was applied to calculate the amounts of carrier and coating materials. Using this method, improved flow characteristics and hardness of the formulation has been achieved by changing the proportion of carrier and coating materials. Further, a 23 factorial design is used and developed LSC using Neusilin (LSC-N1 to LSC-N8) and Fugicalin (LSC-F1 to LSC-F8). The In vitro drug release from these LSC were evaluated in 0.1N HCl and the optimized formulation (LSC-N8) was compared with pure drug (capsule) and marketed product (tablet). The release studies proved that the liquisolid tablets produced higher release profile than pure drug and marketed product due to increase in surface and wetting properties of drug. Thus, LSC confirmed the enhanced dissolution rate of risperidone which in turn helps in improving bioavailability.

Author(s): Shamili Kaparthi and P. R. Sathesh Babu

Abstract | PDF

Share This Article